Ligand Pharmaceuticals Incorporated (LGND)

Market Cap	1.93B
Revenue (ttm)	181.49M
Net Income (ttm)	-132.62M
Shares Out	19.29M
EPS (ttm)	-7.11
PE Ratio	n/a
Forward PE	96.97
Dividend	n/a
Ex-Dividend Date	n/a

Volume	114,223
Open	99.50
Previous Close	101.64
Day's Range	99.50 - 100.00
52-Week Range	77.43 - 129.90
Beta	0.76
Analysts	Strong Buy
Price Target	144.71 (+44.71%)
Earnings Date	May 8, 2025

About LGND

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neurobla...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 18, 1992
• Employees: 68
• Stock Exchange: NASDAQ
• Ticker Symbol: LGND
• Website: https://www.ligand.com

Analyst Forecast

According to 8 analysts, the average rating for LGND stock is "Strong Buy." The 12-month stock price forecast is $144.71, which is an increase of 44.71% from the latest price.

Price Target

$144.71

(44.71% upside)

Analyst Consensus: Strong Buy